Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Malignant Neoplasm in the Neck Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
dasatinib, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Carcinoma of the Head and Neck
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Newark, Delaware • Chicago, Illinois • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas
Interventions
PF-07265028, Sasanlimab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
cetuximab, paclitaxel, carboplatin, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Rochester, New York • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
Interventions
Duvelisib, Docetaxel
Drug
Lead sponsor
Glenn J. Hanna
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced May 21, 2026, 10:15 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
Interventions
Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 10:15 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
Interventions
Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
ixabepilone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced May 21, 2026, 10:15 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
177
States / cities
Little Rock, Arkansas • Marysville, California • Palo Alto, California + 143 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 10:15 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Metastatic Cervical Cancer
Interventions
Best Practice, Hypnotherapy, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced May 21, 2026, 10:15 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
30
States / cities
Mobile, Alabama • Loma Linda, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2008 · Synced May 21, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
72
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma, Urothelial Carcinoma, NSCLC, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
IRX 2, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ALT-803
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Minneapolis, Minnesota • Lebanon, New Hampshire • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
erlotinib hydrochloride, pemetrexed disodium, quality-of-life assessment, intensity-modulated radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, irinotecan hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
8
States / cities
Macon, Georgia • Chattanooga, Tennessee • Jackson, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced May 21, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
cetuximab, placebo, sorafenib tosylate, laboratory biomarker analysis, quality-of-life assessment
Biological · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 21, 2026, 10:15 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
talactoferrin, laboratory biomarker analysis
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced May 21, 2026, 10:15 PM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced May 21, 2026, 10:15 PM EDT